MNKD - MannKind Corp Stock Price, Fair Value and News

4.19USD+0.03 (+0.72%)Market Closed

Market Summary

USD4.19+0.03

Market Closed

0.72%

MNKD Stock Price

View Fullscreen

MNKD RSI Chart

MNKD Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-94.23

Price/Sales (Trailing)

5.65

EV/EBITDA

97.11

Price/Free Cashflow

-134.77

MNKD Price/Sales (Trailing)

MNKD Profitability

EBT Margin

-5.22%

Return on Equity

-0.4%

Return on Assets

-2.51%

Free Cashflow Yield

-0.74%

MNKD Fundamentals

MNKD Revenue

Revenue (TTM)

199.0M

Rev. Growth (Yr)

62.16%

Rev. Growth (Qtr)

14.09%

MNKD Earnings

Earnings (TTM)

-11.9M

Earnings Growth (Yr)

107.81%

Earnings Growth (Qtr)

-18.59%

Breaking Down MNKD Revenue

Last 7 days

2.7%

Last 30 days

-15.4%

Last 90 days

21.3%

Trailing 12 Months

5.1%

How does MNKD drawdown profile look like?

MNKD Financial Health

Current Ratio

3.59

MNKD Investor Care

Shares Dilution (1Y)

2.46%

Diluted EPS (TTM)

-0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	128.4M	158.1M	176.5M	199.0M
2022	70.0M	65.6M	76.2M	99.8M
2021	66.3M	74.5M	81.4M	75.4M
2020	61.8M	61.9M	62.7M	65.1M
2019	41.8M	53.0M	63.1M	63.0M
2018	12.2M	13.9M	16.4M	27.9M
2017	134.0M	93.3M	52.5M	11.7M
2016	0	0	131.1M	174.8M
2012	0	0	43.7M	87.4M
2011	82.3K	71.5K	60.8K	50.0K
2010	0	0	0	93.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MannKind Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	sabella lauren m	sold (taxes)	-79,098	4.63	-17,084	evp chief operating officer
Feb 04, 2024	castagna michael	acquired	99,999	3.27	30,581	chief executive officer
Feb 04, 2024	kay sabrina	acquired	349,998	3.27	107,033	-
Feb 04, 2024	blank burkhard	acquired	499,999	3.27	152,905	evp chief medical officer
Feb 04, 2024	tross stuart a	acquired	49,998	3.27	15,290	chief people & workpl officer
Feb 04, 2024	hooper anthony c	acquired	130,800	3.27	40,000	-
Feb 04, 2024	consiglio ronald j	acquired	81,750	3.27	25,000	-
Feb 04, 2024	sabella lauren m	acquired	49,998	3.27	15,290	evp chief operating officer
Dec 31, 2023	tross stuart a	acquired	3,108	3.09	1,006	chief people & workpl officer
Dec 31, 2023	sabella lauren m	acquired	2,196	3.09	711	evp chief operating officer

Which funds bought or sold MNKD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Stonegate Investment Group, LLC	unchanged	-	16,465	83,805	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-1.21	309,176	1,656,750	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	12.51	201,839	706,168	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-65,382	485,700	-%
Apr 19, 2024	Westside Investment Management, Inc.	unchanged	-	534	2,718	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-1,711	-	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	71.42	567,685	1,068,560	0.06%
Apr 17, 2024	Trivant Custom Portfolio Group, LLC	unchanged	-	134	680	-%
Apr 17, 2024	PEOPLES FINANCIAL SERVICES CORP.	unchanged	-	211	1,084	-%
Apr 16, 2024	TSFG, LLC	unchanged	-	-	-	-%

Are Funds Buying or Selling MNKD?

Are funds buying MNKD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNKD

No. of Funds

Unveiling MannKind Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.66%	15,248,608	SC 13G/A
Jan 25, 2024	blackrock inc.	8.3%	22,297,032	SC 13G/A
Jan 22, 2024	state street corp	4.80%	12,940,395	SC 13G/A
Feb 09, 2023	vanguard group inc	5.19%	13,664,228	SC 13G/A
Feb 08, 2023	state street corp	6.56%	17,258,797	SC 13G/A
Feb 03, 2023	blackrock inc.	8.0%	21,008,795	SC 13G/A
Feb 10, 2022	state street corp	5.19%	13,048,311	SC 13G
Feb 10, 2022	vanguard group inc	5.03%	12,645,574	SC 13G/A
Feb 01, 2022	blackrock inc.	8.4%	20,993,492	SC 13G/A
Feb 10, 2021	vanguard group inc	5.22%	12,291,714	SC 13G

Recent SEC filings of MannKind Corp

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	3	Insider Trading
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Mar 26, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to MannKind Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

MannKind Corp News

Latest updates

MannKind Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	14.1%	58,472,000	51,253,000	48,611,000	40,626,000	36,059,000	32,825,000	18,894,000	11,992,000	12,515,000	22,211,000	23,280,000	17,436,000	18,443,000	15,352,000	15,114,000	16,235,000	15,993,000	14,595,000	15,002,000	17,448,000	16,031,000
Costs and Expenses	9.7%	50,614,000	46,156,000	46,890,000	46,624,000	48,849,000	42,435,000	39,348,000	33,248,000	36,483,000	28,801,000	33,553,000	23,627,000	42,190,000	24,482,000	23,029,000	23,356,000	27,345,000	23,374,000	25,954,000	30,962,000	23,760,000
S&GA Expenses	-18.0%	11,024,000	13,440,000	14,002,000	13,310,000	11,616,000	13,541,000	15,868,000	12,728,000	-9,162,000	17,221,000	20,056,000	17,413,000	-7,554,000	13,899,000	13,670,000	14,350,000	15,721,000	16,666,000	16,609,000	25,673,000	17,974,500
EBITDA Margin	168.4%	0.05	-0.07	-0.19	-0.43	-0.72	-1.22	-1.26	-1.32	-1.00	-0.70	-0.89	-0.66	-	-	-	-	-	-	-	-	-
Interest Expenses	1.5%	2,858,000	2,815,000	6,873,000	2,424,000	2,997,500	2,812,000	6,642,000	2,371,000	2,769,000	2,803,000	3,180,000	6,452,000	6,259,000	1,057,000	1,084,000	1,071,000	1,021,000	4,126,000	564,000	593,000	620,000
Income Taxes	-	1,561,000	-	-	-	-	-	-	-	-	-	-	-	-	-218,000	-	-	-	-	-	-	-
Earnings Before Taxes	72.1%	2,962,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,473,000	-10,252,000	-9,322,000	-14,263,000	-10,370,000	-12,387,000	-14,883,000	-9,749,000
EBT Margin	70.6%	-0.05	-0.18	-0.30	-0.55	-0.88	-1.28	-1.33	-1.34	-1.07	-0.97	-1.16	-0.92	-	-	-	-	-	-	-	-	-
Net Income	-18.6%	1,401,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,255,000	-10,252,000	-9,322,000	-14,263,000	-10,370,000	-12,387,000	-14,883,000	-9,747,000
Net Income Margin	66.1%	-0.06	-0.18	-0.30	-0.55	-0.88	-1.28	-1.33	-1.34	-1.07	-0.97	-1.16	-0.92	-	-	-	-	-	-	-	-	-
Free Cashflow	680.4%	15,804,000	-2,723,000	-14,273,000	-7,155,000	-7,472,000	-28,344,000	-29,148,000	-23,304,000	-17,537,000	-19,430,000	-22,501,000	-13,707,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	48.3%	475	320	313	298	295	294	286	308	321	238	253	319	109	96.00	103	80.00	94.00	95.00	82.00	101	108
Current Assets	65.5%	373	226	230	223	235	218	193	184	219	159	180	288	79.00	66.00	73.00	49.00	61.00	62.00	50.00	70.00	82.00
Cash Equivalents	187.3%	238	83.00	86.00	86.00	70.00	54.00	36.00	67.00	124	52.00	63.00	248	67.00	52.00	63.00	39.00	30.00	30.00	8.00	35.00	71.00
Inventory	5.3%	29.00	27.00	25.00	22.00	22.00	18.00	21.00	8.00	7.00	7.00	7.00	5.00	5.00	5.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00
Net PPE	4.7%	84.00	80.00	70.00	55.00	45.00	41.00	38.00	41.00	37.00	31.00	28.00	27.00	26.00	26.00	26.00	27.00	27.00	27.00	27.00	26.00	26.00
Goodwill	-1.6%	2.00	2.00	2.00	2.00	2.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	26.1%	721	572	574	554	546	532	533	540	531	423	436	493	289	282	282	278	284	280	278	289	283
Current Liabilities	8.0%	104	96.00	97.00	82.00	67.00	60.00	60.00	53.00	48.00	50.00	60.00	73.00	74.00	106	68.00	68.00	66.00	64.00	77.00	78.00	75.00
Retained Earnings	0.0%	-3,229	-3,230	-3,232	-3,227	-3,217	-3,199	-3,200	-3,156	-3,130	-3,100	-3,097	-3,100	-3,049	-3,022	-3,000	-3,001	-2,991	-2,977	-2,967	-2,954	-2,940
Additional Paid-In Capital	0.2%	2,981	2,976	2,969	2,969	2,964	2,960	2,937	2,923	2,918	2,915	2,912	2,886	2,866	2,834	2,829	2,801	2,799	2,791	2,769	2,765	2,763
Shares Outstanding	0.2%	270	270	268	264	264	255	253	252	249	250	249	247	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,084	-	-	-	910	-	-	-	1,266	-	-	-	358	-	-	-	194	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	150.2%	21,678	8,664	2,596	1,156	-2,376	-28,073	-31,982	-18,248	-12,347	-15,184	-21,447	-12,731	235	-13,460	-3,684	-11,219	-5,107	-52,051	-19,728	-11,597	24,988
Share Based Compensation	-17.1%	3,813	4,601	5,580	3,655	2,597	3,622	4,422	2,806	3,160	3,179	3,926	1,935	1,904	1,294	2,185	1,128	944	1,640	2,568	999	1,143
Cashflow From Investing	31.6%	-7,895	-11,549	3,664	13,792	15,010	27,348	2,022	-39,506	-12,579	4,992	-112,532	-31,418	-4,480	-4.00	-150	19,850	-202	3,761	-1,369	-25,033	-244
Cashflow From Financing	50164.0%	141,681	-283	-5,945	1,154	2,825	19,526	-1,776	813	97,370	-590	-51,490	224,977	18,694	2,640	28,188	331	5,042	65,495	-676	3.00	35,967

MNKD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 198,962	$ 99,770	$ 75,442
Expenses:
Cost of goods sold	20,863	16,003	16,833
Research and development	31,283	19,721	12,312
Selling	51,776	53,753	45,528
General and administrative	42,538	37,720	31,889
Asset impairment			106
Loss (gain) on foreign currency transaction	1,916	(4,811)	(6,567)
Loss on purchase commitments			339
Total expenses	190,284	163,880	122,464
Income (loss) from operations	8,678	(64,110)	(47,022)
Other income (expense):
Interest income, net	6,154	2,513	112
Interest expense on financing liability	(9,825)	(9,758)	(1,373)
Interest expense	(15,151)	(15,011)	(15,204)
Interest expense on liability for sale of future royalties	(185)
Loss on available-for-sale securities	(170)	(932)
Loss on extinguishment of debt			(17,200)
Other income (expense)	122	(102)	(239)
Total other expense	(19,055)	(23,290)	(33,904)
Loss before income tax expense	(10,377)	(87,400)	(80,926)
Income tax expense	(1,561)
Net loss	$ (11,938)	$ (87,400)	$ (80,926)
Net loss per share - basic	$ (0.04)	$ (0.34)	$ (0.32)
Net loss per share - diluted	$ (0.04)	$ (0.34)	$ (0.32)
Weighted average shares used to compute net loss per share - basic	267,014	257,092	249,244
Weighted average shares used to compute net loss per share - diluted	267,014	257,092	249,244
Commercial product sales
Revenues:
Total revenues	$ 74,029	$ 56,247	$ 39,168
Collaborations and services
Revenues:
Total revenues	52,954	27,924	36,274
Expenses:
Cost of revenue	41,908	41,494	$ 22,024
Royalties
Revenues:
Total revenues	$ 71,979	$ 15,599

MNKD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 238,480	$ 69,767
Short-term investments	56,619	101,079
Accounts receivable, net	14,901	16,801
Inventory	28,545	21,772
Prepaid expenses and other current assets	34,848	25,477
Total current assets	373,393	234,896
Property and equipment, net	84,220	45,126
Goodwill	1,931	2,428
Other intangible asset	1,073	1,153
Long-term investments	7,155	1,961
Other assets	7,426	9,718
Total assets	475,198	295,282
Current liabilities:
Accounts payable	9,580	11,052
Accrued expenses and other current liabilities	42,036	35,553
Financing liability — current	9,809	9,565
Midcap credit facility - current	20,000
Liability for sale of future royalties - current	9,756
Deferred revenue — current	9,085	1,733
Recognized loss on purchase commitments — current	3,859	9,393
Total current liabilities	104,125	67,296
Mann Group convertible note	8,829	8,829
Accrued interest - Mann Group convertible note	56	55
Financing liability — long term	94,319	94,512
Midcap credit facility - long term	13,019	39,264
Senior convertible notes	226,851	225,397
Liability for sale of future royalties - long term	136,054
Recognized loss on purchase commitments — long term	60,942	62,916
Operating lease liability	3,925	5,343
Deferred revenue — long term	69,794	37,684
Milestone liabilities	3,452	4,524
Total liabilities	721,366	545,820
Commitments and contingencies (Note 16)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2023 and 2022
Common stock, $0.01 par value - 800,000,000 and 400,000,000 shares authorized as of December 31, 2023 and 2022, respectively, and 270,034,495 and 263,793,305 shares issued and outstanding as of December 31, 2023 and 2022, respectively	2,700	2,638
Additional paid-in capital	2,980,539	2,964,293
Accumulated deficit	(3,229,407)	(3,217,469)
Total stockholders' deficit	(246,168)	(250,538)
Total liabilities and stockholders' deficit	$ 475,198	$ 295,282

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

CEO	Dr. Michael E. Castagna Pharm.D.
WEBSITE	mannkindcorp.com
INDUSTRY	Biotechnology
EMPLOYEES	391

MannKind Corp Frequently Asked Questions

What is the ticker symbol for MannKind Corp? What does MNKD stand for in stocks?

MNKD is the stock ticker symbol of MannKind Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MannKind Corp (MNKD)?

As of Tue Apr 23 2024, market cap of MannKind Corp is 1.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNKD stock?

You can check MNKD's fair value in chart for subscribers.

What is the fair value of MNKD stock?

You can check MNKD's fair value in chart for subscribers. The fair value of MannKind Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MannKind Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNKD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MannKind Corp a good stock to buy?

The fair value guage provides a quick view whether MNKD is over valued or under valued. Whether MannKind Corp is cheap or expensive depends on the assumptions which impact MannKind Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNKD.

What is MannKind Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, MNKD's PE ratio (Price to Earnings) is -94.23 and Price to Sales (PS) ratio is 5.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNKD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MannKind Corp's stock?

In the past 10 years, MannKind Corp has provided -0.182 (multiply by 100 for percentage) rate of return.